Sunday, February 5, 2023
Berlin: Students should not call police on migrant sexual offenders
The General Students’ Committee (AStA) of the Free University of Berlin (FU) warned in a circular email not only against a man who has repeatedly sexually harassed and threatened female students for some time now, but also against calling the Berlin police if they come into contact with him. People who meet him and feel harassed by him are strongly advised not to do so. Instead, they should first contact the university’s security service.
Alerting the police could lead to “police violence” according to the council. “We would like to point out that police interventions for people affected by racism are always accompanied by an increased risk of experiencing police violence,” the AStA letter stated. It is said to have been sent to the university groups and student council initiatives last week.
According to the letter, the man has repeatedly appeared at various buildings at the FU, which is dotted around the area of Dahlem in southwestern Berlin. He has been threatening students for several weeks and has behaved in an aggressive and intrusive manner towards women. So far, he has not physically assaulted anyone, but there have been repeated threats of violence. He is said to have stalked one person for some time.
Complaints against migrant continue
Also according to the FU, complaints of harassment continue to be lodged. Upon request, the FU confirmed “that in the past there have been several complaints from university members about harassment on campus by a person not affiliated with the university”. This person has been banned from the campus and measures have been taken to ensure that this ban is adhered to.
For reasons of data protection, it is not possible to say whether this is the same person who was pictured and named in the letter from the AStA. The Berlin police meanwhile confirmed a complaint about a sexual insult from December.
According to the AStA, the alleged racism is not the only reason for not calling the police. From their point of view, the officers are “not sufficiently trained in dealing with exceptional psychological situations”, the letter continued. Therefore, such operations are often “escalated by the unnecessary use of force”.
Such a concern does not take into account the dangers for a potential victim, but rather exonerates the perpetrator in advance, since the latter is often in...
The 90 Miles Mystery Video: Nyctophilia Edition #1285
Before You Click On The "Read More" Link,
Please Only Do So If You Are Over 21 Years Old.
If You are Easily Upset, Triggered Or Offended, This Is Not The Place For You.
Please Leave Silently Into The Night......
The 90 Miles Mystery Box: Episode #1985
You have come across a mystery box. But what is inside?
It could be literally anything from the serene to the horrific,
from the beautiful to the repugnant,
from the mysterious to the familiar.
If you decide to open it, you could be disappointed,
you could be inspired, you could be appalled.
This is not for the faint of heart or the easily offended.
You have been warned.
Saturday, February 4, 2023
Moderna Announces mRNA Vaccine To Treat ‘Sudden’ Surge in Turbo-Cancers
During the recent World Economic Forum in Davos, Switzerland, Moderna CEO Stephane Bancel admitted that he would “like to have mRNA capacity on every continent.”
“The mRNA technology rollout is so concerning,” said Tracy Beanz, news and editorial contributor for The HighWire. “They’d never tested this on humans before March of 2020, and now they’re pushing this lipid nanoparticle into the arms of every citizen on the planet.”
“And they’re not looking to stop with just the [Wuhan coronavirus] COVID vaccines,” continued Beanz. “They’re expanding.” She boasted that Moderna is planning to release mRNA-based vaccines for other common health conditions like MERS, SARS, Marburg virus disease and the Zika fever.
Naturalnews.com reports: Moderna is also developing mRNA-based vaccines for respiratory syncytial virus (RSV) and an aggressive type of skin cancer.
The Big Pharma company’s RSV vaccine is already in phase 3 of trial testing, with data released by the company claiming it is 83.7 percent effective at preventing moderate cases of the disease, which is defined as a bout of RSV with two or more symptoms. The company further claimed that the vaccine candidate is 82.4 percent effective at dealing with a severe case of RSV, defined by having three or more symptoms.
Moderna hopes to get the Food and Drug Administration to approve of the company’s RSV vaccine by the end of the year.
The company’s skin cancer mRNA vaccine, which it is developing with Merck, is allegedly showing promise in its phase 2 trial.
Data released by the company claimed that the mRNA vaccine, when used in combination with an immunotherapy drug called Keytruda sold by Merck, reduced the risk of death or recurrence of melanoma in high-risk patients by 44 percent compared with treatment using only Keytruda.
The phase 2 trial enrolled 157 participants. Due to its so-called early successes, Bancel is preparing to move Moderna toward holding larger phase 3 trials. These trials will involve the company testing the vaccine and immunotherapy drug combination with other kinds of cancer, with Bancel claiming that it “should work in...
Subscribe to:
Posts (Atom)